E-cadherin Antikörper

Produktnummer ABIN335399

Produktdetails anti-E-cadherin Antikörper

Target: E-cadherin (CDH1) (Cadherin 1, Type 1, E-Cadherin (Epithelial) (CDH1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser E-cadherin Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))

Spezifität: Human.

Aufreinigung: Purified

Immunogen: 6F9 is a mouse monoclonal IgG1 antibody obtained by fusion of P3-X63-Ag 8,653 mouse myeloma cells with spleen cells from a BABL/c mouse immunized with affinity purified 80 kD extracellular fragments of E-cadherin derived from tryptic digestion of A-431 human vulva carcinoma cells.

Klon: 6F9

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: 6F9 recognizes both the 120 kD E-cadherin and its 80 kD trypsin-resistant extracellular part. 6F9 is suitable for immunoblotting, immunocytochemistry and immunohistochemistry on frozen when using a PBS buffer containing 0.1 mM CaCl 2 and 0.1 mM MgCl 2 . Optimal antibody dilution should be determined by titration, recommended range is 1:25 - 1:100 for immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, and 1:50 - 1:500 for immunoblotting applications.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Referenzen für anti-E-cadherin Antikörper (ABIN335399)

Ghadimi, Behrens, Hoffmann, Haensch, Birchmeier, Schlag: "Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling." in: European journal of cancer (Oxford, England : 1990), Vol. 35, Issue 1, pp. 60-5, (1999) (PubMed).

Zschiesche, Schönborn, Behrens, Herrenknecht, Hartveit, Lilleng, Birchmeier: "Expression of E-cadherin and catenins in invasive mammary carcinomas." in: Anticancer research, Vol. 17, Issue 1B, pp. 561-7, (1997) (PubMed).

Moll, Mitze, Frixen, Birchmeier: "Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas." in: The American journal of pathology, Vol. 143, Issue 6, pp. 1731-42, (1994) (PubMed).

Böhm, Totzeck, Birchmeier, Wieland: "Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer." in: Clinical & experimental metastasis, Vol. 12, Issue 1, pp. 55-62, (1994) (PubMed).

Otto, Birchmeier, Schmidt, Hinke, Schipper, Rübben, Raz: "Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas." in: Cancer research, Vol. 54, Issue 12, pp. 3120-3, (1994) (PubMed).

Mayer, Johnson, Leitl, Jauch, Heiss, Schildberg, Birchmeier, Funke: "E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration." in: Cancer research, Vol. 53, Issue 7, pp. 1690-5, (1993) (PubMed).

Frixen, Behrens, Sachs, Eberle, Voss, Warda, Löchner, Birchmeier: "E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells." in: The Journal of cell biology, Vol. 113, Issue 1, pp. 173-85, (1991) (PubMed).

Schipper, Frixen, Behrens, Unger, Jahnke, Birchmeier: "E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis." in: Cancer research, Vol. 51, Issue 23 Pt 1, pp. 6328-37, (1991) (PubMed).

Details zu E-cadherin

Target: E-cadherin (CDH1) (Cadherin 1, Type 1, E-Cadherin (Epithelial) (CDH1))

Andere Bezeichnung: E-Cadherin / Cadherin-1 (CDH1 Produkte)

Hintergrund: Cadherins constitute a family of transmembrane glycoproteins involved in Ca 2+ -dependent cell-cell interactions. The members of this family are differentially expressed in various tissues. They function in the maintenance of tissue integrity and morphogenesis. Cadherins are divided into type I and type II subgroups. Type I cadherins include epithelial cadherin (E-cadherin, cadherin-1 or uvomorulin), neural cadherin (N-cadherin or cadherin-2), placental cadherin (P-cadherin or cadherin-3) and retinal cadherin (R-cadherin or cadherin-4), whereas kidney cadherin (K-cadherin or cadherin-6) and osteoblast cadherin (OB-cadherin or cadherin-11) are type II cadherins. One of the best characterized cadherins is E-cadherin, a 120 kD transmembrane glycoprotein consisting of an 80 kD extracellular and a 40 kD transmembrane and cytoplasmic part. The extracellular domains of E-cadherin are responsible for calcium binding which allows for homophilic interaction with other E-cadherin molecules on the same cell and neighbouring cells. In addition, E-cadherin can interact heterophilically with integrin alpha E beta 7 . The cytoplasmic domain of E-cadherin is linked to the actin cytoskeleton through the associated cytoplasmic catenin proteins, thus establishing a complex localized to adherens junctions. In carcinomas E-cadherin is frequently downregulated, which is consistent with its function of an invasion suppressor in normal epithelia.

Pathways: WNT Signalweg, Sensory Perception of Sound, Cell-Cell Junction Organization, Tube Formation